Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Flu cases are rising with a strain that makes older people sicker - 2Monetary Freedom Guide: Plan Your Future
- 3WHO issues guidance on GLP-1 drugs for obesity
- 4January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- 5Warming winters lead to more nitrate pollution in the drinking water near farms
- Really focusing on Succulents: Tips and Procedures
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- Mobility exercises are an important part of fitness as we age. Here are some tips
- Terminal cancer diagnosis announced by JFK's granddaughter
- PHOTO ESSAY: Summer camp for kids with autoimmune diseases
- At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’
- Flu surges across U.S. as doctor visits reach highest level since 1997
- Share your pick for the miniature headphones that you generally suggest!
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
